Antitumor effect of pingyangmycin in combination with monoclonal antibody 3G11 directed against type IV collagenase

Xiu Jun Liu, Zhi Gang Ouyang, Yao Dai, Xiao Yun Liu, Yong Su Zhen

Research output: Contribution to journalArticle

Abstract

Objective: To study the antitumor effects of the combination of pingyangmycin (PYM) and monoclonal antibody(mAb) 3G11 directed against type IV collagenase. Methods: Immunoreactivity of mAb 3G11 to type IV collagenase and various tumor cells was determined by ELISA and the cytotoxicity of PYM and PYM plus 3G11 was examined by MTT assay. Antitumor effects in vivo were evaluated by using subcutaneously transplanted hepatoma 22 tumor model in mice. Results: mAb 3G11 showed immunoreactivity to type IV collagenase, mouse hepatoma 22 (H22) cells, human hepatoma HepG2 cells, and human prostatic carcinoma DU145 cells. As compared with free PYM, PYM plus 3G11 showed stronger cytotoxicity to these tumor cells. Synergetic effect was found at a certain dose range. When administered intravenously (iv × 6, every other day), PYM (10 mg/kg) plus 3G11 (60 mg/kg) inhibited the subcutaneous growth of hepatoma 22 in mice by 85.4%, whereas free PYM at 10 mg/kg and mAb 3G11 at 60 mg/kg used separately inhibited tumor growth by 70.0% and 49.6%, respectively. Conclusions: PYM in combination with mAb 3G11 shows much stronger antitumor effects than equivalent doses of free PYM or mAb 3G11. The combination might be potentially useful in cancer therapy.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalChinese Journal of Cancer Prevention and Treatment
Volume14
Issue number3
StatePublished - Feb 2007

Fingerprint

Collagenases
Monoclonal Antibodies
Hepatocellular Carcinoma
Neoplasms
bleomycetin
Hep G2 Cells
Growth
Enzyme-Linked Immunosorbent Assay
Carcinoma

Keywords

  • Antibodies, monoclonal
  • Bleomycin/pharmacology
  • Cell line, tumor
  • Liver neoplasms/pathology
  • Mice, nude

ASJC Scopus subject areas

  • Oncology

Cite this

Antitumor effect of pingyangmycin in combination with monoclonal antibody 3G11 directed against type IV collagenase. / Liu, Xiu Jun; Ouyang, Zhi Gang; Dai, Yao; Liu, Xiao Yun; Zhen, Yong Su.

In: Chinese Journal of Cancer Prevention and Treatment, Vol. 14, No. 3, 02.2007, p. 177-180.

Research output: Contribution to journalArticle

@article{26865e0f14d94711920d0fd2de6255af,
title = "Antitumor effect of pingyangmycin in combination with monoclonal antibody 3G11 directed against type IV collagenase",
abstract = "Objective: To study the antitumor effects of the combination of pingyangmycin (PYM) and monoclonal antibody(mAb) 3G11 directed against type IV collagenase. Methods: Immunoreactivity of mAb 3G11 to type IV collagenase and various tumor cells was determined by ELISA and the cytotoxicity of PYM and PYM plus 3G11 was examined by MTT assay. Antitumor effects in vivo were evaluated by using subcutaneously transplanted hepatoma 22 tumor model in mice. Results: mAb 3G11 showed immunoreactivity to type IV collagenase, mouse hepatoma 22 (H22) cells, human hepatoma HepG2 cells, and human prostatic carcinoma DU145 cells. As compared with free PYM, PYM plus 3G11 showed stronger cytotoxicity to these tumor cells. Synergetic effect was found at a certain dose range. When administered intravenously (iv × 6, every other day), PYM (10 mg/kg) plus 3G11 (60 mg/kg) inhibited the subcutaneous growth of hepatoma 22 in mice by 85.4{\%}, whereas free PYM at 10 mg/kg and mAb 3G11 at 60 mg/kg used separately inhibited tumor growth by 70.0{\%} and 49.6{\%}, respectively. Conclusions: PYM in combination with mAb 3G11 shows much stronger antitumor effects than equivalent doses of free PYM or mAb 3G11. The combination might be potentially useful in cancer therapy.",
keywords = "Antibodies, monoclonal, Bleomycin/pharmacology, Cell line, tumor, Liver neoplasms/pathology, Mice, nude",
author = "Liu, {Xiu Jun} and Ouyang, {Zhi Gang} and Yao Dai and Liu, {Xiao Yun} and Zhen, {Yong Su}",
year = "2007",
month = "2",
language = "English (US)",
volume = "14",
pages = "177--180",
journal = "Chinese Journal of Cancer Prevention and Treatment",
issn = "1673-5269",
publisher = "Chinese Journal of Cancer Prevention and Treatment, Editorial board",
number = "3",

}

TY - JOUR

T1 - Antitumor effect of pingyangmycin in combination with monoclonal antibody 3G11 directed against type IV collagenase

AU - Liu, Xiu Jun

AU - Ouyang, Zhi Gang

AU - Dai, Yao

AU - Liu, Xiao Yun

AU - Zhen, Yong Su

PY - 2007/2

Y1 - 2007/2

N2 - Objective: To study the antitumor effects of the combination of pingyangmycin (PYM) and monoclonal antibody(mAb) 3G11 directed against type IV collagenase. Methods: Immunoreactivity of mAb 3G11 to type IV collagenase and various tumor cells was determined by ELISA and the cytotoxicity of PYM and PYM plus 3G11 was examined by MTT assay. Antitumor effects in vivo were evaluated by using subcutaneously transplanted hepatoma 22 tumor model in mice. Results: mAb 3G11 showed immunoreactivity to type IV collagenase, mouse hepatoma 22 (H22) cells, human hepatoma HepG2 cells, and human prostatic carcinoma DU145 cells. As compared with free PYM, PYM plus 3G11 showed stronger cytotoxicity to these tumor cells. Synergetic effect was found at a certain dose range. When administered intravenously (iv × 6, every other day), PYM (10 mg/kg) plus 3G11 (60 mg/kg) inhibited the subcutaneous growth of hepatoma 22 in mice by 85.4%, whereas free PYM at 10 mg/kg and mAb 3G11 at 60 mg/kg used separately inhibited tumor growth by 70.0% and 49.6%, respectively. Conclusions: PYM in combination with mAb 3G11 shows much stronger antitumor effects than equivalent doses of free PYM or mAb 3G11. The combination might be potentially useful in cancer therapy.

AB - Objective: To study the antitumor effects of the combination of pingyangmycin (PYM) and monoclonal antibody(mAb) 3G11 directed against type IV collagenase. Methods: Immunoreactivity of mAb 3G11 to type IV collagenase and various tumor cells was determined by ELISA and the cytotoxicity of PYM and PYM plus 3G11 was examined by MTT assay. Antitumor effects in vivo were evaluated by using subcutaneously transplanted hepatoma 22 tumor model in mice. Results: mAb 3G11 showed immunoreactivity to type IV collagenase, mouse hepatoma 22 (H22) cells, human hepatoma HepG2 cells, and human prostatic carcinoma DU145 cells. As compared with free PYM, PYM plus 3G11 showed stronger cytotoxicity to these tumor cells. Synergetic effect was found at a certain dose range. When administered intravenously (iv × 6, every other day), PYM (10 mg/kg) plus 3G11 (60 mg/kg) inhibited the subcutaneous growth of hepatoma 22 in mice by 85.4%, whereas free PYM at 10 mg/kg and mAb 3G11 at 60 mg/kg used separately inhibited tumor growth by 70.0% and 49.6%, respectively. Conclusions: PYM in combination with mAb 3G11 shows much stronger antitumor effects than equivalent doses of free PYM or mAb 3G11. The combination might be potentially useful in cancer therapy.

KW - Antibodies, monoclonal

KW - Bleomycin/pharmacology

KW - Cell line, tumor

KW - Liver neoplasms/pathology

KW - Mice, nude

UR - http://www.scopus.com/inward/record.url?scp=77953443155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953443155&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953443155

VL - 14

SP - 177

EP - 180

JO - Chinese Journal of Cancer Prevention and Treatment

JF - Chinese Journal of Cancer Prevention and Treatment

SN - 1673-5269

IS - 3

ER -